- Home
- BIIB vs SUI Comparison
BIIB vs SUI Comparison
Compare BIIB & SUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- SUI
- Stock Information
- Founded
- BIIB 1978
- SUI 1975
- Country
- BIIB United States
- SUI United States
- Employees
- BIIB N/A
- SUI N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- SUI Real Estate Investment Trusts
- Sector
- BIIB Health Care
- SUI Real Estate
- Exchange
- BIIB Nasdaq
- SUI Nasdaq
- Market Cap
- BIIB 19.9B
- SUI 17.1B
- IPO Year
- BIIB 1991
- SUI 1993
- Fundamental
- Price
- BIIB $124.40
- SUI $124.89
- Analyst Decision
- BIIB Buy
- SUI Buy
- Analyst Count
- BIIB 27
- SUI 10
- Target Price
- BIIB $220.50
- SUI $136.60
- AVG Volume (30 Days)
- BIIB 1.8M
- SUI 792.9K
- Earning Date
- BIIB 04-23-2025
- SUI 04-28-2025
- Dividend Yield
- BIIB N/A
- SUI 2.88%
- EPS Growth
- BIIB 40.28
- SUI N/A
- EPS
- BIIB 11.18
- SUI 0.71
- Revenue
- BIIB $9,675,900,000.00
- SUI $3,190,400,000.00
- Revenue This Year
- BIIB N/A
- SUI N/A
- Revenue Next Year
- BIIB N/A
- SUI N/A
- P/E Ratio
- BIIB $11.75
- SUI $184.71
- Revenue Growth
- BIIB N/A
- SUI 0.81
- 52 Week Low
- BIIB $128.51
- SUI $110.98
- 52 Week High
- BIIB $238.00
- SUI $147.83
- Technical
- Relative Strength Index (RSI)
- BIIB 32.01
- SUI 49.62
- Support Level
- BIIB $128.75
- SUI $127.61
- Resistance Level
- BIIB $144.07
- SUI $131.35
- Average True Range (ATR)
- BIIB 3.72
- SUI 2.58
- MACD
- BIIB -1.21
- SUI -0.19
- Stochastic Oscillator
- BIIB 11.38
- SUI 38.32
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About SUI Sun Communities Inc.
Sun Communities is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently owns a portfolio of 666 properties, which includes 350 manufactured housing communities, 179 residential vehicle communities, and 137 marina properties. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.